UB
Therapeutic Areas
CNBX Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cannabics® RCC-33 | Colorectal Cancer | Preclinical |
| Cannabics® MLN-33 | Melanoma | Discovery |
| Cannabics® BRST-33 | Breast Cancer | Discovery |
| Cannabics® PRST-33 | Prostate Cancer | Discovery |
| Cannabics® PLP-33 | Pre-cancerous Polyps | Preclinical |
| Cannabics® SR | Cancer-related Anorexia Cachexia Syndrome (CACS) | Phase 3 |
| NP-01 | Neuropsychiatry (Unspecified) | Discovery |
| NP-02 | Neuropsychiatry (Unspecified) | N/A |
Leadership Team at CNBX Pharmaceuticals
GY
Gabriel Yariv
Executive Chairman of the Board
EB
Eyal Barad
Co-Founder, CEO, Board Member
DI
Dr. Inbar Maymon-Pomeranchik
Independent Board Member
DG
Dr. Gil Feiler
Independent Board Member, Head of Advisory Board
SY
Shaul Yemal
Independent Board Member
DS
Dr. Sanja Goldberg
CTO
DI
Dr. Ilya Reznik
Head of Neuropsychiatry Development
DL
Dr. Lior Eshdat
VP Intellectual Property